US regulator orders makers of weight-loss drugs to carry blindness risk warning

The FDA has mandated that manufacturers of GLP-1 weight-loss drugs include warnings about a heightened risk of a rare but severe eye condition that can lead to permanent blindness. This move follows growing concerns over the safety profile of these medications, which have surged in popularity for their effectiveness in weight management. The decision underscores the importance of comprehensive drug safety monitoring and the need for patients to be fully informed about potential side effects. For those considering these treatments, this development highlights the critical balance between benefits and risks.